Skip to main content
. 2021 Jun 19;43(2):199–239. doi: 10.1210/endrev/bnab019

Figure 6.

Figure 6.

Gene mutations leading to an activation of Wnt signaling (cluster 3) and derived molecular targets for a personalized therapy. Mutations in MAML3 and CSDE1 activate Wnt/ß-catenin signaling. Highlighted in red are potential drugs that address the molecular changes in cluster 3 PPGLs and are in preclinical evaluation.